journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Cancer

journal
https://www.readbyqxmd.com/read/29156299/outcomes-from-ovarian-cancer-screening-in-the-plco-trial-histologic-heterogeneity-impacts-detection-overdiagnosis-and-survival
#1
Sarah M Temkin, Eric A Miller, Goli Samimi, Christine D Berg, Paul Pinsky, Lori Minasian
AIM: A mortality benefit from screening for ovarian cancer has never been demonstrated. The aim of this study was to evaluate the screening outcomes for different histologic subtypes of ovarian cancers. METHODS: Women in the screening arm of the Prostate, Lung, Colorectal and Ovarian Screening Trial underwent CA-125 and transvaginal ultrasound annually for 3-5 years. We compared screening test characteristics (including overdiagnosis) and outcomes by tumour type (type II versus other) and study arm (screening versus usual care)...
November 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29156298/european-research-on-electrochemotherapy-in-head-and-neck-cancer-eureca-project-results-from-the-treatment-of-mucosal-cancers
#2
Christina Caroline Plaschke, Giulia Bertino, James A McCaul, Juan J Grau, Remco de Bree, Gregor Sersa, Antonio Occhini, Ales Groselj, Cristobal Langdon, Derrek A Heuveling, Maja Cemazar, Primoz Strojan, C Rene Leemans, Marco Benazzo, Francesca De Terlizzi, Irene Wessel, Julie Gehl
AIM: Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours. PATIENT AND METHODS: Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area...
November 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29154173/prognostic-value-of-tumour-infiltrating-lymphocytes-in-small-her2-positive-breast-cancer
#3
Carmen Criscitiello, Vincenzo Bagnardi, Giancarlo Pruneri, Andrea Vingiani, Angela Esposito, Nicole Rotmensz, Giuseppe Curigliano
BACKGROUND: The standard treatment for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancer (BC) is still controversial. Our aim was to assess the prognostic role of tumour-infiltrating lymphocytes (TILs) in patients with stage pT1a-b HER2-positive BC. PATIENTS AND METHODS: Haematoxylin and eosin slides from node-negative, pT1a-b HER2-positive BC surgical specimens were retrieved from pathology archives to assess TILs and their association with outcome...
November 15, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29149761/crizotinib-achieves-long-lasting-disease-control-in-advanced-papillary-renal-cell-carcinoma-type-1-patients-with-met-mutations-or-amplification-eortc-90101-create-trial
#4
Patrick Schöffski, Agnieszka Wozniak, Bernard Escudier, Piotr Rutkowski, Alan Anthoney, Sebastian Bauer, Jozef Sufliarsky, Carla van Herpen, Lars H Lindner, Viktor Grünwald, Branko Zakotnik, Evelyne Lerut, Maria Debiec-Rychter, Sandrine Marréaud, Michela Lia, Tiana Raveloarivahy, Sandra Collette, Laurence Albiges
PURPOSE: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-). EXPERIMENTAL DESIGN: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Patients were attributed to MET+/MET- sub-cohorts by the sequencing of exons 16-19 of the MET gene in tumour tissue...
November 14, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29149760/patterns-of-relapse-in-poor-prognosis-germ-cell-tumours-in-the-getug-13-trial-implications-for-assessment-of-brain-metastases
#5
Y Loriot, L Pagliaro, A Fléchon, J Mardiak, L Geoffrois, P Kerbrat, C Chevreau, R Delva, F Rolland, C Theodore, G Roubaud, G Gravis, J C Eymard, J P Malhaire, C Linassier, M Habibian, A L Martin, F Journeau, M Reckova, C Logothetis, A Laplanche, G Le Teuff, S Culine, K Fizazi
BACKGROUND: The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and demonstrated that a dose-dense regimen improves progression-free survival in patients with an unfavourable decline. We investigated the pattern of relapse for patients included in GETUG 13. METHODS: We conducted an analysis of relapse events in patients from GETUG 13. Baseline procedures before inclusion in the trial comprised a thoraco-abdomino-pelvic computed tomography scan and a magnetic resonance imaging of the brain...
November 14, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29145039/a-first-in-human-phase-i-study-of-sar125844-a-selective-met-tyrosine-kinase-inhibitor-in-patients-with-advanced-solid-tumours-with-met-amplification
#6
Eric Angevin, Gianluca Spitaleri, Jordi Rodon, Katia Dotti, Nicolas Isambert, Stefania Salvagni, Victor Moreno, Sylvie Assadourian, Corinne Gomez, Marzia Harnois, Antoine Hollebecque, Analia Azaro, Alice Hervieu, Karim Rihawi, Filippo De Marinis
PURPOSE: Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation. METHODS: This was a phase I dose-escalation (3 + 3 design [50-740 mg/m(2)]) and dose-expansion study. In the dose escalation, patients had high total MET (t-MET) expression by immunohistochemistry (IHC) or MET amplification by fluorescence in situ hybridisation...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29145038/precision-medicine-for-patients-with-advanced-biliary-tract-cancers-an-effective-strategy-within-the-prospective-moscato-01-trial
#7
Loic Verlingue, David Malka, Adrien Allorant, Christophe Massard, Charles Ferté, Ludovic Lacroix, Etienne Rouleau, Nathalie Auger, Maud Ngo, Claudio Nicotra, Thierry De Baere, Lambros Tselikas, Bakar Ba, Stefan Michiels, Jean-Yves Scoazec, Valérie Boige, Michel Ducreux, Jean-Charles Soria, Antoine Hollebecque
BACKGROUND: Recommended treatments of patients with advanced biliary tract cancer (aBTC) are limited to one chemotherapy doublet. Nevertheless, efficacy of treatment personalisation for aBTCs is supported by accumulating evidences but remains to be evaluated. PATIENTS AND METHODS: Patients with aBTCs included in the prospective clinical trial MOSCATO-01 were treated by at least one previous systemic treatment, had an ECOG performance status of 0-1, and at least one tumour site accessible to biopsy...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29145037/time-to-diagnosis-and-treatment-for-cancer-patients-in-the-netherlands-room-for-improvement
#8
Charles C W Helsper, Nicole N F van Erp, Petra P H M Peeters, Niek N J de Wit
BACKGROUND & AIM: Reducing the duration of the diagnostic cancer care pathway is intensively pursued. The aim of this study was to chart the diagnostic pathway for the five most common cancers in the Netherlands. METHODS: A retrospective cohort study using cancer patients' anonymised primary care data (free text and coded) linked to the Netherlands Cancer Registry. We determined the median duration of the following: 1. Primary care intervals (IPCs): the first cancer-related general practitioner consultation to referral, 2...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29145036/liver-immunotolerance-and-hepatocellular-carcinoma-patho-physiological-mechanisms-and-therapeutic-perspectives
#9
REVIEW
Gaël S Roth, Thomas Decaens
At the moment of the diagnosis of hepatocellular carcinoma (HCC), 70% of patients have only access to palliative treatments, with very few therapeutic options. Liver immunology is very specific, and liver immunotolerance is particularly developed because of the constant and massive influx of antigens. Deregulation of hepatic immunotolerance is implicated in chronic liver diseases development and particularly in liver carcinogenesis. For these reasons, HCC may be an excellent candidate for anticancer immunotherapies such as immune checkpoint inhibitors targeting CTLA-4 and PD-L1/PD-1...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29132062/risk-of-early-onset-prostate-cancer-associated-with-occupation-in-the-nordic-countries
#10
Kathryn Hughes Barry, Jan Ivar Martinsen, Michael C R Alavanja, Gabriella Andreotti, Aaron Blair, Johnni Hansen, Kristina Kjærheim, Stella Koutros, Elsebeth Lynge, Pär Sparèn, Laufey Tryggvadottir, Elisabete Weiderpass, Sonja I Berndt, Eero Pukkala
BACKGROUND: Early-onset prostate cancer is often more aggressive and may have a different aetiology than later-onset prostate cancer, but has been relatively little studied to date. We evaluated occupation in relation to early- and later-onset prostate cancer in a large pooled study. METHODS: We used occupational information from census data in five Nordic countries from 1960 to 1990. We identified prostate cancer cases diagnosed from 1961 to 2005 by linkage of census information to national cancer registries and calculated standardised incidence ratios (SIRs) separately for men aged 30-49 and those aged 50 or older...
November 10, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29132061/synchronous-peritoneal-metastases-of-small-bowel-adenocarcinoma-insights-into-an-underexposed-clinical-phenomenon
#11
Laura M Legué, Geert A Simkens, Geert-Jan M Creemers, Valery E P P Lemmens, Ignace H J T de Hingh
BACKGROUND: The aim of this population-based study was to provide insight into the incidence, risk factors and treatment-related survival of patients with peritoneal metastases (PM) of small bowel adenocarcinoma (SBA). METHODS: Data from the Netherlands Cancer Registry were used. All patients diagnosed with SBA between 2005 and 2014 were included. The influence of patient and tumour characteristics on the odds of developing PM was analysed. Subsequently, for all further analyses, patients without synchronous PM of SBA were excluded...
November 10, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29128692/coast-cisplatin-ototoxicity-attenuated-by-aspirin-trial-a-phase-ii-double-blind-randomised-controlled-trial-to-establish-if-aspirin-reduces-cisplatin-induced-hearing-loss
#12
Simon J Crabb, Karen Martin, Julia Abab, Ian Ratcliffe, Roger Thornton, Ben Lineton, Mary Ellis, Ronald Moody, Louise Stanton, Angeliki Galanopoulou, Tom Maishman, Thomas Geldart, Mike Bayne, Joe Davies, Carolynn Lamb, Sanjay Popat, Johnathan K Joffe, Chris Nutting, John Chester, Andrew Hartley, Gareth Thomas, Christian Ottensmeier, Robert Huddart, Emma King
BACKGROUND: Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common mechanism, involving reactive oxygen species in the inner ear. Aspirin has been shown to minimise gentamicin-induced ototoxicity. We, therefore, tested the hypothesis that aspirin could also reduce ototoxicity from cisplatin-based chemotherapy. METHODS: A total of 94 patients receiving cisplatin-based chemotherapy for multiple cancer types were recruited into a phase II, double-blind, placebo-controlled trial and randomised in a ratio of 1:1 to receive aspirin 975 mg tid and omeprazole 20 mg od, or matched placebos from the day before, to 2 days after, their cisplatin dose(s), for each treatment cycle...
November 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29126088/in-the-immuno-oncology-era-is-anti-pd-1-or-anti-pd-l1-immunotherapy-modifying-the-sensitivity-to-conventional-cancer-therapies
#13
Sandrine Aspeslagh, Margarida Matias, Virginia Palomar, Laurent Dercle, Emilie Lanoy, Jean-Charles Soria, Sophie Postel-Vinay
INTRODUCTION: The advent of anti-programmed death receptor-1/ligand-1 antibodies (anti-PD(L)1) is profoundly changing the therapeutic strategy of oncology. As anti-PD(L)1 modulate tumour microenvironment, it might impact sensitivity to conventional cancer therapy (CCT). Therefore, we explored whether sensitivity to CCT was different before and after anti-PD(L)1 therapy. METHODS: Patients who started anti-PD(L)1 treatment at Gustave Roussy Cancer Centre between February 2012 and December 2015, and who received at least one line of CCT immediately before and immediately after anti-PD(L)1, were eligible...
November 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29117576/the-utility-of-anti-m%C3%A3-llerian-hormone-in-the-diagnosis-and-prediction-of-loss-of-ovarian-function-following-chemotherapy-for-early-breast-cancer
#14
R A Anderson, J Mansi, R E Coleman, D J A Adamson, R C F Leonard
AIM: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. METHODS: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed...
November 5, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29107861/is-post-mastectomy-radiation-therapy-contributive-in-pn0-1mi-breast-cancer%C3%A2-patients-results-of-a-french-multi-centric-cohort
#15
Violaine Forissier, Agnès Tallet, Monique Cohen, Jean-Marc Classe, Fabien Reyal, Nicolas Chopin, Chafika Mazouni, Pierre Gimbergues, Emile Daraï, Pierre Emmanuel Colombo, Pierre Azuar, Eric Lambaudie, Gilles Houvenaeghel
AIM: To assess the value of post-mastectomy radiation therapy (PMRT) to breast cancer (BC) patients with no or minimal lymph node (LN) involvement. MATERIALS AND METHODS: We retrospectively analysed a French multi-centric cohort of 4283 patients treated by mastectomy and axillary dissection, with or without PMRT, between 1980 and 2013. Practices were analysed for three treatment periods (1980-1999, 2000-2005 and 2006-2013). The impact of PMRT on loco-regional recurrence (LRR), disease-free survival (DFS), BC-specific survival and overall survival was assessed in pN0-1mi patients using multivariate analyses (logistic regression and Cox model)...
November 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29107860/site-of-childhood-cancer-care-in-the-netherlands
#16
A M J Reedijk, M van der Heiden-van der Loo, O Visser, H E Karim-Kos, J A Lieverst, J G de Ridder-Sluiter, J W W Coebergh, L C Kremer, R Pieters
BACKGROUND: Due to the complexity of diagnosis and treatment, care for children and young adolescents with cancer preferably occurs in specialised paediatric oncology centres with potentially better cure rates and minimal late effects. This study assessed where children with cancer in the Netherlands were treated since 2004. METHODS: All patients aged under 18 diagnosed with cancer between 2004 and 2013 were selected from the Netherlands Cancer Registry (NCR) and linked with the Dutch Childhood Oncology Group (DCOG) database...
November 3, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29103666/identification-of-single-nucleotide-polymorphisms-of-the-pi3k-akt-mtor-pathway-as-a-risk-factor-of-central-nervous-system-metastasis-in-metastatic-breast-cancer
#17
Emilie Le Rhun, Nicolas Bertrand, Aurélie Dumont, Emmanuelle Tresch, Marie-Cécile Le Deley, Audrey Mailliez, Matthias Preusser, Michael Weller, Françoise Revillion, Jacques Bonneterre
INTRODUCTION: The PI3K-AKT-mTOR pathway may be involved in the development of central nervous system (CNS) metastasis from breast cancer. Accordingly, herein we explored whether single nucleotide polymorphisms (SNPs) of this pathway are associated with altered risk of CNS metastasis formation in metastatic breast cancer patients. METHODS: The GENEOM study (NCT00959556) included blood sample collection from breast cancer patients treated in the neoadjuvant, adjuvant or metastatic setting...
November 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29102858/weekly-cabazitaxel-plus-prednisone-is-effective-and-less-toxic-for-unfit-metastatic-castration-resistant-prostate-cancer-phase-ii-spanish-oncology-genitourinary-group-sogug-trial
#18
Miguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, Eva María Fernández Parra, Ovidio Fernández Calvo, María Ochoa de Olza, Laura Muinelo Romay, Urbano Anido, Montserrat Domenech, Susana Hernando Polo, José Ángel Arranz Arija, Cristina Caballero, María José Juan Fita, Daniel Castellano
AIM: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficacy and safety of CBZ as a weekly schedule for 'unfit' mCRPC patients after docetaxel failure. METHODS: In this single arm phase II study. CBZ was weekly administered in 1-hour infusion on days 1, 8, 15 and 22, every 5 weeks at 10 mg/m(2) to eligible 'unfit' patients; oral prednisone (5 mg) was administered twice a day...
November 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29100194/cognitive-decline-after-major-oncological-surgery-in-the-elderly
#19
M Plas, E Rotteveel, G J Izaks, J M Spikman, H van der Wal-Huisman, B van Etten, A R Absalom, M J E Mourits, G H de Bock, B L van Leeuwen
BACKGROUND: Elderly patients undergoing oncological surgery experience postoperative cognitive decline. The aims of this study were to examine the incidence of cognitive decline 3 months after surgery and identify potential patient-, disease- and surgery-related risk factors for postoperative cognitive decline in onco-geriatric patients. METHODS: A consecutive series of elderly patients (≥65 years) undergoing surgery for the removal of a solid tumour were included (n = 307)...
October 31, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29096157/the-association-between-health-related-quality-of-life-scores-and-clinical-outcomes-in-metastatic-castration-resistant-prostate-cancer-patients-exploratory-analyses-of-affirm-and-prevail-studies
#20
Tomasz M Beer, Kurt Miller, Bertrand Tombal, David Cella, De Phung, Stefan Holmstrom, Cristina Ivanescu, Konstantina Skaltsa, Shevani Naidoo
BACKGROUND: Our exploratory analysis examined the association between health-related quality of life (HRQoL) (baseline and change over time) and clinical outcomes (overall survival [OS]/radiographic progression-free survival [rPFS]) in metastatic castration-resistant prostate cancer (mCRPC). METHODS: HRQoL, OS and rPFS were assessed in phase III trials comparing enzalutamide with placebo in chemotherapy-naïve (PREVAIL; NCT01212991) or post-chemotherapy (AFFIRM; NCT00974311) mCRPC...
October 30, 2017: European Journal of Cancer
journal
journal
30413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"